National Institute of Infectious Diseases: Statement-Fourth Iteration of COVID-19 Treatment Trial Underway
November 26, 2020
November 26, 2020
WASHINGTON, Nov. 26 -- The U.S. Department of Health and Human Services' National Institute of Allergy and Infectious Diseases issued the following statement on Nov. 25:
The National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health, today announced that the fourth iteration of the Adaptive COVID-19 Treatment Trial (ACTT-4) has begun to enroll hospitalized adults with coronavirus disease 2019 (COVID-19) who require supplemental oxyge . . .
The National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health, today announced that the fourth iteration of the Adaptive COVID-19 Treatment Trial (ACTT-4) has begun to enroll hospitalized adults with coronavirus disease 2019 (COVID-19) who require supplemental oxyge . . .